达拉非尼联合曲美替尼与多靶点酪氨酸激酶抑制剂二线治疗 BRAF V600E突变放射性碘难治性晚期甲状腺癌的疗效

陈光亮 ,  何霞云 ,  黄乃思 ,  陈嘉莹 ,  桑友洲 ,  杨亚男 ,  沈春英 ,  王玉龙 ,  王宇 ,  季冬梅

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (10) : 865 -870.

PDF (498KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (10) : 865 -870. DOI: 10.12007/j.issn.0258‐4646.2026.10.001
论著

达拉非尼联合曲美替尼与多靶点酪氨酸激酶抑制剂二线治疗 BRAF V600E突变放射性碘难治性晚期甲状腺癌的疗效

作者信息 +

Efficacy of dabrafenib plus trametinib and multitargeted tyrosine kinase inhibitor as second-line therapy for BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer

Author information +
文章历史 +
PDF (509K)

摘要

目的 比较达拉非尼联合曲美替尼 (D+T) 与多靶点酪氨酸激酶抑制剂 (TKI) 作为二线治疗在放射性碘难治性晚期甲状腺癌患者中的疗效,分析基因突变对疗效的潜在影响。方法 收集接受以D+T方案或TKI方案为基础的二线治疗的BRAF V600E突变放射性碘难治性晚期甲状腺癌患者39例 (含9例低分化型甲状腺癌),其中D+T组30例,TKI组9例。采用倾向性评分重叠加权法控制混杂偏倚,比较2组患者中位无进展生存期 (PFS) 的差异。结果 经重叠加权后,2组患者基线特征达到均衡。D+T组中位PFS为13.3个月 (95%CI:6.7~19.9),TKI组为3.5个月 (95%CI:1.8~5.2)。加权Cox回归和随访时间截至30个月的敏感性分析结果均显示,D+T组进展或死亡风险呈降低趋势 (HR分别为0.613和0.650)。探索性分析结果显示,D+T方案的PFS获益仅在无TERT启动子、TP53和PI3K/AKT通路相关基因突变患者中显著 (HR<1),在基因突变患者中未显示明显获益。结论 在放射性碘难治性晚期甲状腺癌患者的二线治疗中,D+T方案较TKI方案显示出更长的中位PFS,伴随基因突变可能影响PFS获益。D+T方案可能为更优的二线治疗选择。

Abstract

Objective To compare the efficacy of dabrafenib plus trametinib (D+T) with multitargeted tyrosine kinase inhibitor (TKI) as second-line therapy for BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer,and to explore the potential impact of coexisting gene mutations on efficacy. Methods We retrospectively analyzed 39 patients with BRAF V600E-mutant radioactive iodine-refractory advanced thyroid cancer,including nine with poorly differentiated thyroid cancer. The patients received D+T-based (n = 30) or TKI-based (n = 9) second-line therapy. Propensity score overlap weighting was used to adjust confounding factors,and progression-free survival (PFS) was compared between groups. Results After overlap weighting,baseline characteristics were balanced between groups. Median PFS was 13.3 months (95%CI:6.7-19.9) in the D+T group and 3.5 months (95%CI:1.8-5.2) in the TKI group. Both weighted Cox regression and sensitivity analysis with follow-up truncated at 30 months showed a trend toward reduced risk of progression or death with D+T-based therapy,with hazard ratio (HR) of 0.613 and 0.650,respectively. Exploratory analyses revealed that the PFS benefit of D+T was apparent only in patients without TERT promoter,TP53,or PI3K/AKT pathway-related gene mutations,but not in those with these mutations. Conclusion In second-line therapy for radioactive iodine-refractory advanced thyroid cancer,D+T therapy showed longer median PFS than TKI therapy,and this benefit may be influenced by coexisting gene mutations. Overall,D+T therapy may represent a more favorable second-line option than TKI therapy.

关键词

甲状腺癌 / 二线治疗 / 达拉非尼 / 曲美替尼 / 多靶点酪氨酸激酶抑制剂

Key words

thyroid cancer / second-line therapy / dabrafenib / trametinib / multitargeted tyrosine kinase inhibitor

引用本文

引用格式 ▾
陈光亮,何霞云,黄乃思,陈嘉莹,桑友洲,杨亚男,沈春英,王玉龙,王宇,季冬梅. 达拉非尼联合曲美替尼与多靶点酪氨酸激酶抑制剂二线治疗 BRAF V600E突变放射性碘难治性晚期甲状腺癌的疗效[J]. 中国医科大学学报, 2026, 55(10): 865-870 DOI:10.12007/j.issn.0258‐4646.2026.10.001

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Machlah Y M,Srasra L M,Theurer S,et al. Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR- (P) DTC [J].Endocr Relat Cancer,2026,33 (2):e250461. DOI:10.1530/ERC-25-0461.

[2]

Schlumberger M,Tahara M,Wirth L J,et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer [J].N Engl J Med,2015,372 (7):621-630. DOI:10.1056/NEJMoa1406470.

[3]

Brose M S,Nutting C M,Jarzab B,et al. Sorafenib in radioactive iodine-refractory,locally advanced or metastatic differentiated thyroid cancer:a randomised,double-blind,phase 3 trial [J].Lancet,2014,384 (9940):319-328. DOI:10.1016/S0140-6736(14)60421-9.

[4]

Díaz Vico T, Martínez-Amores Martínez B,Mihic Góngora L,et al. Systemic therapeutic options in radioiodine-refractory differentiated thyroid cancer:current indications and optimal timing [J].Cancers,2025,17 (11):1800. DOI:10.3390/cancers17111800.

[5]

Brose M S,Robinson B G,Sherman S I,et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer:updated results from the phase 3 COSMIC-311 trial [J].Cancer,2022,128 (24):4203-4212. DOI:10.1002/cncr.34493.

[6]

Xing M Z,Haugen B R,Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer [J].Lancet,2013,381 (9871):1058-1069. DOI:10.1016/S0140-6736(13)60109-9.

[7]

Araque K A,Gubbi S,Klubo-Gwiezdzinska J. Updates on the management of thyroid cancer [J].Horm Metab Res,2020,52 (8):562-577. DOI:10.1055/a-1089-7870.

[8]

Saba N F,Ismaila N,Adkins D,et al. Systemic treatment of thyroid cancer:ASCO guideline [J].J Clin Oncol,2026,44 (14):1349-1372. DOI:10.1200/JCO-26-00235.

[9]

Kish J K,Chatterjee D,Wan Y,et al. Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer:a real-world study of clinical effectiveness in the United States [J].Adv Ther,2020,37 (6):2841-2852. DOI:10.1007/s12325-020-01362-6.

[10]

Hanahan D. Hallmarks of cancer:then and now,and beyond [J].Cell,2026,189 (8):2254-2277. DOI:10.1016/j.cell.2025.12.049.

[11]

Song Y S,Park Y J. Genomic characterization of differentiated thyroid carcinoma [J]. Endocrinol Metab (Seoul),2019,34 (1):1-10. DOI:10.3803/EnM.2019.34.1.1.

[12]

Chung J H. BRAF and TERT promoter mutations:clinical application in thyroid cancer [J].Endocr J,2020,67 (6):577-584. DOI:10.1507/endocrj.EJ20-0063.

基金资助

“癌症、心脑血管、呼吸和代谢性疾病防治研究”国家科技重大专项(2026ZD0553100)

AI Summary AI Mindmap
PDF (498KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉